Grace Therapeutics (NASDAQ:GRCE) Releases Earnings Results, Beats Expectations By $0.04 EPS

Grace Therapeutics (NASDAQ:GRCE) posted its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04, FiscalAI reports.

Grace Therapeutics Price Performance

NASDAQ:GRCE traded down $0.04 on Thursday, reaching $1.81. 85,170 shares of the company’s stock were exchanged, compared to its average volume of 345,807. The firm has a market cap of $38.08 million, a price-to-earnings ratio of -1.53 and a beta of 0.43. Grace Therapeutics has a 52 week low of $1.67 and a 52 week high of $5.18. The stock has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $2.76.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GRCE shares. Wall Street Zen lowered Grace Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Thursday, October 15th. Finally, Zacks Research upgraded Grace Therapeutics to a “hold” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $6.00.

About Grace Therapeutics

Grace Therapeutics, Inc. (NASDAQ: GRCE) is a clinical-stage biopharmaceutical company developing therapies for rare and life-threatening medical conditions. The company focuses on drug-delivery technologies intended to improve the administration, absorption, and therapeutic performance of established pharmaceutical compounds. Grace Therapeutics’ lead candidate is GTx-104, an investigational injectable formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a serious form of bleeding around the brain.